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ABSTRACT
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generation of amplitude-modulated pulse-width modulation
(AMPWM) signals for use in treating neurological dysfunc
tion via cranial neurostimulation, where the AMPWM signal
is specifically designed to minimize the electrical impedance
of the tissues of the head. A low-frequency carrier signal is
determined for the AMPWM signal by measuring EEG activ
ity at a reference site or sites, generally corresponding with
the location of Suspected brain dysfunction. Carrier signal
frequency is variably related to critical frequency compo
nents of the EEG power spectral density, determined from
statistical analysis of amplitudes and variability, and dynami
cally changed as a function of time to prevent entrainment.
The AMPWM signal is presented to a subject via a plurality of
neurostimulation delivery modes for therapeutic use.
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METHOD AND APPARATUS FOR UTILIZING
AMPLITUDE-MODULATED PULSE-VIDTH
MODULATION SIGNALS FOR
NEUROSTIMULATION AND TREATMENT OF
NEUROLOGICAL DISORDERS USING
ELECTRICAL STMULATION
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CROSS REFERENCE TO RELATED PATENT
DOCUMENTS
10

This application is a divisional application of U.S. patent
application Ser. No. 1 1/490,255, filed Jul. 21, 2006 now U.S.
Pat. No. 7,715,910, which is a continuation application of
U.S. patent application Ser. No. 10/357,503, filed Feb. 4,
2003 now abandoned, which is based upon and claims the
benefit of priority from U.S. Provisional Application No.
60/353,234, filed on Feb. 4, 2002. The disclosures of the prior
applications are hereby incorporated by reference herein in
their entirety.
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forehead of a user.

A learning-relaxation device of U.S. Pat. No. 4,315.502
has both lights for pulsing signals and sound means for a
pulsing Sound signal as well as a control means that can
individually vary the light and Sound signals.
U.S. Pat. No. 4,834,701 to Masaki shows a device similar
25
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U.S. Pat. No. 3,884,218 to Robert A. Monroe shows a

method for inducing sleep by amplitude modulating a pleas

frequency of a user. The term “entrainment” began to be
accepted for such devices: “This phenomenon, in which one
regular cycle locks into another, is now called entrainment, or
mode locking.” (Gleick, Chaos: Making of a New Science
1987, Penguin Books, p. 293). An article entitled “Alpha
Brain Waves & Biofeedback Training in the December 1972
Popular Electronics show a system that uses a person's own
EEG signal to modulate a tone generator which, in turn, then
drives a speaker heard by the same person. The device
allowed a person to “hear his or her own brain signals in an
attempt to Voluntarily control the frequency. A similar device
that allows a person to “see' his or her own brain waves is
shown in an article entitled “Mind Power: Alpha' in the July
1976 Radio-Electronics.

U.S. Pat. No. 5,036,858 to John L. Carter, Harold L. Rus
sell and Len Ochs shows the use of EEG electrodes attached
45

50

controlled.

to those used by Monroe and Oster with first and second
generators with frequencies above 16 hertz and a frequency
difference of 4 to 16 hertz sounded to lower the brain wave

BACKGROUND OF INVENTION AND
DESCRIPTION OF RELATED ART

In the 1960s and early 1970s, Robert Monroe of the
Monroe Institute of Applied Sciences explored the effects of
Sound on the brain and discovered that he could produce a
driving or entrainment of brain waves. Dr. Gerald Oster, a
biophysicist, also investigating the effects of Sound on the
brain, discovered that pulsations called binaural beats
occurred in the brain when tones of different frequencies were
presented separately to each ear. The beat frequency equals
the frequency difference between the two tones. Both Monroe
and Oster began using electronic oscillators to provide tones
with frequency, purity and intensity that can be precisely

in U.S. Pat. No. 4,227,516 to Meland et al. in which a first

signal above the delta-beta frequency range is modulated by
signal within that range and applied to electrodes on the

FIELD OF THE INVENTION

The present invention relates generally to the field of pro
ducing and applying electrical energy to the brain, and to the
therapeutic uses of the electrical energy and an apparatus for
administering the same. More specifically, the present inven
tion relates to a system for controlling neurostimulation
where the neurostimulation comprises an electrical signal
whose characteristics minimize composite tissue impedances
of the head, and more specifically yet, to a computer con
trolled system for automatic adjustment of neurostimulation
signals related to critical frequency components of an
acquired EEG signal, generally obtained at or near a region of
Suspected brain dysfunction.
The electrical activity, or EEG, of human brains has tradi
tionally been used as a diagnostic marker for abnormal brain
function and related symptomatic dysfunction. Often, trau
matic disturbances such as mechanical injury, Social stress,
emotional stress and chemical exposure cause neurophysi
ological changes that will manifest as EEG abnormalities.
However, disruption of this abnormal EEG activity by the
application of external electrical energy, henceforth referred
to as a neurostimulation signal, may cause yet further neuro
physiological changes in traumatically disturbed brain tis
Sues, as evidenced in an amelioration of the EEG activity, and
hence are beneficial to an individual. Such therapeutic inter
vention has proven useful in pain therapy and in treating a
number of non-painful neurological deficits such as depres
Sion, attention deficit disorder, and many others.

2
ing Sound with a delta-rhythm signal that is referred to as an
“EEG sleep signal.” The 218 patent uses sound to induce
sleep by creating a specific signal that coaxes the brain into a
relaxed state. This signal chosen in the 218 patent is chosen
based upon its proximity to signals that are strong during
normal sleep.
U.S. Pat. No. 4,191,175 to Nagle shows a method and
apparatus for repetitively "producing a noise-like signal for
inducing a hypnotic or anesthetic effect . . . . by creating
frequency bursts of digital pulses that are then passed through
a pink noise filter to eliminate frequencies above a certain
cut-off. The resultant signal is then passed through a band
pass filter and used to drive an audible signal source.
An apparatus for electrophysiological stimulation is shown

55

to the head of the user along with an amplifier for determining
a current brain wave frequency of a user, which is communi
cated to a computer processor. A new frequency is generated
which is between the current brain wave frequency and a
desired brain wave frequency and is within a predetermined
range of the current brain wave frequency. This has become
known as electroencephalographic entrainment feedback if it
is used to “lock” the current brain wave frequency into a
desired frequency.
U.S. Pat. No. 5,365,939 to Len Ochs provides a method of
“exercising the brain by using a device producing audio and
visual stimulation to move a user's brain wave frequency
back and forth between predetermined frequency levels.
In U.S. Pat. No. 6,081,743 to John L. Carter, Harold L.

60
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Russell, W. Daniel Vaughn and Robert R. Austin, a method for
treating an individual is described by determining a brain
wave frequency which corresponds to a highest evoked
response of the individual, entraining the brain wave fre
quency to the brain wave frequency corresponding to the
highest evoked response, and then maintaining the brainwave
at that frequency for a predetermined length of time. The
highest evoked response is described as the highest EEG
response or the highest cerebral blood flow (CBF) of the
individual or even some other measure.

US 8,280,502 B2
3
Two patents in application at the time of the disclosure of
the present invention relate to the present invention. In Appli
cation No. 20010003799 by Birinder B. Boveja an apparatus
and method for adjunct (add-on) therapy utilizing an external
stimulator is described to stimulate a cranial nerve according
to a predetermined program.
In Application No. 20010007950 by Richard B. North et.
al. a neurostimulation system and method is described that
includes an implantable stimulator and patient interactive
computer. Also, the 950 application requires patient interac

4
account for this fact. Because of the nature of this impedance,
a higher frequency signal will pass through the tissues with
much less attenuation.
SUMMARY OF THE INVENTION

10

tion.

Prior methods of neurostimulation for therapeutic pur
poses have in many ways attempted to ameliorate brain func
tioning by providing the brain with electrical energy that is
designed to be a reflection of the brain's own activity, often
with the intent of modifying the brain electricity to follow, or
entrain to, a desired frequency, range of frequencies, or rela
tionship among frequencies, or alternately to target theoreti
cally and empirically derived frequency states as a goal of
training ortherapy. However, little attention has been given to
signal design for overcoming the complex and composite
impedance presented by the tissues of the head. Such signals,
when properly constructed, will limit attenuation of neuro
stimulation signals for improved effectiveness in patient

15

25

treatment.

Regarding the concept of conductivity, it is known that the
tendency of any conductive material to limit the flow of
electrical charge, otherwise known as electrical current, is
known as impedance. In general terms, attenuation of current
flow is proportional to the magnitude of a material’s imped
ance. The impedance of a Substance is a function of its mate
rial and physical properties. Environmental factors, such as
temperature, also influence the impedance of a material. Most
significant to the disclosure of the present invention is the
relationship between impedance of a material and the fre
quency of the electrical signal being conducted through the

30

EEG measurements.
35

material.

In its most fundamental terms, three electrical effects gov
ern impedance: resistance, capacitance and inductance.
Resistance is a fundamental form of impedance that is con
stant intime. Therefore, the frequency of a signal has no effect
on resistance. However, both capacitive and inductive effects
are functions of frequency. Inductive reactance, the formal
name for impedance due to inductance, is proportional to
frequency. Thus, the higher the frequency of a signal is, the
higher will its corresponding inductive reactance be. Capaci
tive reactance, the formal name for impedance due to capaci
tive effects, is inversely proportional to frequency. Thus, as a
signals frequency increases, the impedance of a material due
to capacitance decreases. For very high frequencies, capaci
tive reactance can become very small, and the resulting
attenuation of the flow of current will be correspondingly

40

less.

55

The head is comprised of a series of tissues that can be
approximately thought of as composite layers Surrounding
the brain. Specifically, these layers of tissue include the der
mal layers of the scalp, the skull, the meninges, the cerebral
spinal fluid that bathes the brain, and the brain itself including
both healthy tissues and unhealthy tissues such as lesion
matterforming in the region of damage. The impedance of the
tissues of the head is known to be complex in nature, that is,
they have both a resistive component and a capacitive com
ponent. Thus, the overall impedance of these tissues will be a
function of signal frequency because of capacitive reactance,
and an electrical circuit model of these impedances must

The present invention is based on the discovery that certain
neurostimulation signals can provide an optimal effect on the
tissues of the brain, while eliminating conscious patient per
ception of the signal.
Thus, the invention is directed towards a method of treating
one or more neurological dysfunctions. The method com
prises taking a first measurement of the EEG of a subject
afflicted with at least one type of the neurological dysfunction
in order to obtain EEG results and evaluating the EEG results
to determine whether any region of the subject's brain pos
sesses irregular activity as compared to other regions of the
Subject's brain. A determination of a dominant frequency is
separately made for each of the regions of the subjects brain
that possess irregular activity by examining the EEG results
from each the regions of the Subject's brain that possess
irregular activity. Finally, the method comprises an adminis
tration of an anti-neurological dysfunction therapy to the
Subject. The anti-neurological dysfunction therapy comprises
inducing a neurostimulation signal directed to the regions of
the Subject's brain that possess irregular activity for a time
sufficient to normalize the EEG of the regions of the subjects
brain that possess irregular activity. Additionally, further
EEG measurements from the regions of the subjects brain
that possess irregular activity are monitored during the
administration of the therapy and the neurostimulation signal
is adjusted based on any detected changes in the additional

45

50

60

65

The invention is also directed to an apparatus for neuro
stimulating a Subject. The apparatus comprises a computing
device that is operatively coupled to a neurostimulator, and a
series of EEG sensors that are coupled to the neurostimulator.
The EEG sensors are configured (1) to be attached to the
subject, (2) to monitor EEG results of a subject, and (3) to
administer neurostimulation signals to the Subject. Addition
ally, the EEG sensors preferably comprise at least one posi
tive contact, at least one negative contact, and at least one
ground contact.
In accordance with the disclosure herein, an object of the
present invention is to generate an electrical signal for the
purposes of neurostimulation that also minimizes the effect of
tissue impedance to the improved flow of electrical energy to
body tissues.
It is a further object to pass extremely low power signals
with minimal attenuation into Subjects who possess a high
sensitivity to neurostimulation signals.
It is a further object to use an electrical signal referred to as
an amplitude-modulated pulse-width modulation
(AMPWM) signal. An AMPWM signal is characterized by a
high frequency component that is modulated by a low fre
quency carrier for stimulation purposes.
It is a further object to use pulse-width modulation and/or
amplitude control of the high frequency component of the
AMPWM signal in order to control the electrical energy level
present in a neurostimulation signal.
It is a further object of the present invention to use an
AMPWM signal in neurostimulation in order to disentrain an
EEG signal. Disentrainment involves the prevention of the
EEG signal from locking into a particular frequency or fre
quency range, and to cause, rather, the redistribution of EEG
spectral energy. Additionally, it is an object of the present
invention for the AMPWM signal to not maintain a given

US 8,280,502 B2
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frequency for a period of time Sufficient to cause dysfunc
tional entrainment such as that which occurs in an epileptic
seizure.

A further object of the present invention is to provide a
means of constantly assessing power spectral density or other
frequency related Statistics of EEG signals, and using the
frequency related Statistics from the EEG signals to manage
the low frequency component of an AMPWM neurostimula
tion signal so as to prevent entrainment to any specific fre
quency, and to distribute energy uniformly.
A further object is to provide a means of entraining EEG
signals by controlling the low-frequency component of an
AMPWM neurostimulation signal.
A further object is to provide a means of controlling the low
frequency component of an AMPWM signal so that the fre
quency of the low frequency component is determined as a
function of either a constant offset in time or a frequency
analysis driven offset determined as a function of time.
Another object of the present invention is to provide a
means of delivering a neurostimulation signal to regions of
the scalp corresponding to suspected regions of brain dys
function by inducing the neurostimulation signal into EEG
sensors that are concurrently used for measurement of EEG
signals.
Another object of the present invention is to provide neu
rostimulation in which electrical currents are passed through
Suspected regions of brain dysfunction through EEG sensors
which are placed in a manner so that the region of the brain of
the subject in which a dysfunction is located is in the area of
placements of EEG sensors.
Another object is to provide for the utilization of an
AMPWM signal for delivery of neurostimulation through a
photic means, such as rapid pulsing of light-emitting diodes,
in which the light intensity is controlled by pulse width modu
lation of the high frequency component of the AMPWM
signal.
Another object of the present invention is to provide a
means of modifying the low-frequency component of an
AMPWM signal to relate to frequency components of EEG
signals, the means being accomplished by any number of
frequency analysis techniques.
Another object is to provide a system for neurostimulation
that includes a means for acquiring EEG signals from a Sub
ject, analyzing the EEG signals for frequency components
and generating an AMPWM signal which is delivered to the
subject for either the disentrainment or the entrainment of
EEG activity of the subject for therapeutic purposes.
Another object is to provide a means of determining Sus
pected regions of brain dysfunction in a Subject by acquiring
EEG data from a number of scalp sites of the subject, analyz
ing the EEG data for frequency components and assignment
to standard bands of EEG (e.g. delta, theta, etc.), determining
the electrical energy in each of the standard bands by analysis
in order to determine a statistic that is a function of total power
in the band to include but not limited to sum of amplitude, or
root-mean-square, or root Square summation; and variability
to include but not limited to variance or standard deviation,

and using the statistic magnitude as a function of EEG fre
quency range as an indicator of brain dysfunction.
A further object is to provide for an enhanced means of
determining brain dysfunction related to patient symptoms by
measuring sites correlating to known systemic functions (e.g.
pain, speech, movement) and performing the previously
described statistical analysis.

5

10

15

25

30

35

6
A further object is to provide a means of using the statistics
obtained from the previously described statistical analysis to
create a visual graphic corresponding to regions of the brain
for comparative purposes.
A further object of the present invention is to provide a
means of delivering neurostimulation by using more than one
EEG amplifier for multi-site neurostimulation, and wherein
an AMPWM signal is delivered either via photic means or
directly to suspected regions of brain dysfunction via EEG
sensors operatively coupled with an EEG amplifier.
A further object of the present invention is to provide
methods of controlling neurostimulation signal parameters
Such as signal energy level, frequency of the low frequency
component of an AMPWM signal, phase offset of multiple
signals, start time and duration through a user interface.
A further object is to provide for selection of a neurostimu
lation delivery mode.
A further object is to provide a method of assuring EEG
lead interface integrity, for both EEG acquisition purposes
and neurostimulation purposes, by testing using an algorithm
to analyze a measure EEG signal to determine lead interface
integrity. This algorithm detects random electrical noise,
which is a sign of poor interface integrity.
A further object of the present invention is to provide
neurostimulation for other purposes of enhancing brain activ
ity, Such as brainwave training.
A further object is to provide a means of correlating EEG
data to observed events and/or perceived events by provision
of an interface control for marking data either by a patient or
a clinician during neurostimulation.
These and other objects, advantages and features of this
invention will be apparent from the following description
taken with reference to the accompanying drawings, wherein
is shown a preferred embodiment of the invention.
BRIEF DESCRIPTION OF THE DRAWINGS

40
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FIG. 1 illustrates a view of the apparatus.
FIG. 2 illustrates a graphic representation of the neuro
stimulation signal. It is a representation for illustrative pur
poses only and it is not intended to limit the scope of the signal
used in the present invention in any way.
FIG. 3 presents a model of the apparatus of the present
invention in regards to tissue impedance.
FIG. 4 illustrates another view of the apparatus.
DETAILED DESCRIPTION OF THE PREFERRED
EMBODIMENTS

The present invention is directed towards a method and an
apparatus Suitable for the treatment of neurological dysfunc
tions.
55

60

The term “optical unit is intended to define an apparatus
that is used on or in close proximity to the eyes. By close
proximity, it is meanta distance from the eyes of a Subject that
is effective for the transmittal of a light pulse into the eyes of
the subject. Preferably, close proximity will not exceed one
foot in distance from the subject. The structure of the optical
unit may be worn on the face of the patient, such as optical
device or goggles, or it may be located in a separate structure,
Such as a stand that is held near the face or even a hand-held

65

mask. Further, the optic unit may be placed at an angle to the
eyes of the Subject. Additionally, the optic unit may be posi
tioned behind the subject and use mirrors or other reflective
devices (such as a white wall) to reflect the light pulse into the

US 8,280,502 B2
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eyes of the subject. However, in no way is this definition
intended to limit the ultimate structure the optical unit may

8
brain. One of skill in the neurological arts would recognize
which regions of the brain are interrelated with other regions

take.

of the brain.

The term “neurological dysfunction' is intended to define
a group of disorders in which one or more regions of a Sub
jects brain operate at frequencies which are different from
the predetermined frequency for that region of the brain or
from the predetermined frequencies of the other regions of the
Subject’s brain. Examples of neurological dysfunctions
include traumatic brain injury, post traumatic stress disorder,
post stroke paralysis, post traumatic brain injury paralysis,
cerebral palsy, headache, depression, post chemotherapy
cognitive, mood and fatigue disorder, fibromyalgia, memory

For example, in one method of choosing the treatment
sites, the choice is determined by the regions of EEG-slowing
specific to an individual, regardless of the diagnosis. In this
method, it is the presence and pattern of EEG-slowing at any
of the standard neurological 10-20 sites (as selected by the
International 10-20 EEG Site Placement Standard) that is the
indication of the appropriateness of an region of the brain for
treatment. The EEG-slowing pattern also determines where
on the scalp electrodes will be placed for treatment.
Because EEG slowing that is associated with fatigue, poor
short-term memory, and attention problems is likely to

loss, coma, attention deficit disorder, etc. However, the

present invention is not to be construed as being limited to the
treatment of these listed examples.
The term “irregular activity” is intended to define the EEG
frequency of an region of the Subject’s brain which does not
match the predetermined EEG activity of the remaining
regions of the subjects brain. Additionally, the term “irregu
laractivity” is also intended to define an EEG frequency of an
region of the subject's brain that matches the EEG activity of
the remaining regions of the Subject's brain, but with a high
degree of variance. Irregular activity is determined by ana
lyzing the frequency bands of the region of the brain being
investigated and identifying eithera higher band amplitude or
a lower band amplitude than is predetermined for that region.
Examples of potential irregular activity include amplitude
abnormalities in which the measured peak-to-peak micro
volts is over 14 microvolts (abnormally high) or in which the
measured microvolts is under 5 Volts from peak-to-peak (ab
normally low) or possesses a standard deviation of over 3
microvolts. However, these are examples only. One of ordi
nary skill would recognize what a proper benchmark would
be for each subject.
The term “neurostimulation signal' is intended to define a
signal transmitted by the neurostimulator to a subject for the
purpose of normalizing the brainwave activity of regions of
the Subject's brain that possess irregular activity. The neuro
stimulation signal is determined on a subject by Subject basis
and is changed in relation to a shift in the region's dominant
frequency. There is typically a reduction in variability as EEG
changes occur. This is evidenced by a shift in the dominant
frequency more towards the typical frequencies and ampli
tudes that were predetermined for that region of the subjects

10

15

reasonable directive: FP1, F7, F3, C3, F1, AF7, F5, AF3 and

possibly temporal sites, T3 & T5 (according to the Interna
tional 10-20 EEG Site Placement Standard). The amplitudes
and standard deviations from the image data determine the
order of treatment for these sites.

25

The imaging data is preferably gathered by sequentially
recording from each of 21 sites. These data are preferably
processed through a Fast Fourier Transform (FFT) computa
tion which produces quantitative data that shows the average
microvolts and the standard deviation for each frequency
component of the EEG signal at each site. A preferred method
of treatment is to identify those sites that have the highest
standard deviation as shown in the FFT results and treat them

30
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first. Treatment can be accomplished by placing two pairs of
electrodes (one positive and one negative comprise a pair) on
each of the four sites having the highest measured amplitudes.
It is the unique EEG pattern of the individual, however, that
is the key to the most efficient treatment. The determination of
treatment sites applies to any diagnostic category of neuro
logical dysfunction and the determination is individualized
by the quantitative data from each individuals brainwave
data. Therefore, it is not possible to specify a standard set of
sites for any given, or all, diagnostic categories. However,
there is a broad diagnostic classification called EEG-slowing
and that this category can permit the selection of predeter
mined sites from which to direct the treatment of choice.

45

brain.
The term “normalization' is intended to define the result of

the administration of a neurostimulation signal to regions of
the subjects brain that correspond to the regions of the sub
jects brain that possess irregular activity. The neurostimula
tion signal is intended to “normalize' or adjust the brainwave
frequency of the regions of the Subject’s brain that possess
irregular activity to reflect the predetermined frequency of the
region of the subjects brain that is being treated.
The term “dominant frequency’ is intended to define the
frequency in the EEG measurements taken from an area of the
Subject’s brain that possesses the highest Voltage amplitude.
The present invention is directed towards the alleviation of
symptoms of neurological disorders caused by irregular EEG
activity in a subject’s brain. The alleviation of the symptoms
is accomplished by administering a neurostimulation signal
to the regions of the subject’s brain that are related to those
regions of the Subject's brain that possess irregular activity.
These related regions of the subject’s brain can include
regions that possess irregular activity, or other regions of the

involve functional deficits in the left frontal lobes of the

brains, placing electrodes on any of the following sites is a
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Therefore, given the above information one of ordinary skill
would understand how to select a region of the brain for
treatment on a subject by Subject basis.
The neurostimulation signal is administered by modulat
ing a high frequency component, which can be further pulse
width modulated for control of the energy level, with a low
frequency carrier. It is the preferred intent of the present
invention to “disentrain the brain's electrical activity, that is,
to not target or lock into a particular frequency, but rather to
redistribute existing energy to all frequencies in the normal
spectra of the brain EEG in a typically uniform manner.
However, the present invention does not preclude the utiliza
tion of the neurostimulation signal for the purposes of
entrainment.
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The present invention also embodies a method of focusing
a neurostimulation signal directly on a suspected dysfunc
tional region of the brain. This is possible because tissue
impedances are minimized by the design of the neurostimu
lation signal. The neurostimulation signal possesses a greater
ability to directly reach damaged regions of the brain rather
than simply following the outer-most tissues around the scalp
and thereby bypassing the damaged region of the brain.
Another advantage is achieved by inducing the neurostimu
lation signal directly into EEG sensors. This advantage is that
the neurostimulation signal can be strategically placed to
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present a conduction path through the damaged region of the
brain, while concurrently measuring the EEG signal at the
dysfunctional regions, thus providing a direct link between
the measured EEG signals and the neurostimulation signals
being delivered directly to the dysfunctional region.
A method for treating a subject with the method of the
present invention preferably includes the generation of an
electrical neurostimulation signal characterized by a high
frequency pulse train modulated by a low frequency carrier
signal. A means of providing for variable levels of electrical
power may be accomplished by using either pulse width
modulation of the high frequency pulse train, as in the pre
ferred embodiment of the present invention, or variable
amplitudes of the same pulses. Preferably, the frequency of
the high frequency pulse train is at least one order of magni
tude greater than the frequency of the low frequency carrier
signal. It is preferred that the high frequency pulse be in the
range of 43 to 1,000,000 hertz. It is more preferred that the
high frequency pulse be in the range of 1,000 to 100,000
hertz. It is even more preferred that the high frequency pulse
be in the range of 10,000 to 20,000 hertz. It is most preferred
that the high frequency pulse be 15,000 hertz.
The low frequency carrier signal is variably related to
critical frequency components of the EEG power spectral
density, determined from Statistical analysis of amplitudes
and variability. The low frequency carrier signal is deter
mined from information obtained by measuring EEG activity
at a reference site or sites that generally corresponds with the
location of suspected brain dysfunction, and the low fre
quency carrier signal is dynamically changed as a function of
time to prevent entrainment. This is performed by changing
the frequency offset (as described below) at predetermined
time intervals. It is preferred that the low frequency carrier
signal be typical of a brainwave EEG. It is more preferred that
the low frequency carrier signal be in the range of 1-42 hertz.
The combination of (1) the high frequency pulse train as it
is modulated by (2) the low frequency carrier signal, hence
forth referred to as an AMPWM signal, provides a means of
minimizing the effect of tissue impedances of the head. How
ever, no limitation of the present invention to AMPWM sig
nals alone is intended by this abbreviation. Any signal that
possess both (1) and (2) as defined above is intended to be
encompassed by the present invention.
In general, as will be discussed in greater detail in Subse
quent sections of this disclosure, the electrical impedance of
tissues of the head decreases with increased electrical signal
frequency. Thus, the high frequency pulse train component of
the AMPWM signal passes through the head tissues with less
attenuation than the low frequency carrier signals typically
used in already known neurostimulation methods. Further,
the low frequency carrier signal component of the neuro
stimulation signal in essence serves to turn on and off the high
frequency signal component with a frequency that is gener
ally related to the range of frequencies present in an EEG
signal. Thus, the low frequency carrier signal component may
be produced at frequencies commonly used for therapeutic
purposes in neurostimulation devices, such as entrainment or
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10-20 EEG Site Placement Standard.

25

30

35

etc. However, this list is not intended to be exclusive.

The method preferably comprises taking a first measure
ment of the EEG of a subject afflicted with at least one type of

A determination of a dominant frequency of the Subjects
brain is made from the evaluating the EEG results from the
regions of the Subject's brain that possess irregular activity.
Preferably, the evaluation involves the correlation of the EEG
signals into a graphic image of the Subject's brain. Even more
preferably, the graphic image is evaluated and new EEG
signals from the Subject's brain are taken in order to ensure
that the first EEG signals were accurate and in order to deter
mine a dominant frequency from the regions of the Subjects
brain that have been confirmed as possessing irregular activ
ity.
Finally, the method comprises an administration of an anti
neurological dysfunction therapy to the Subject. The anti
neurological dysfunction therapy comprises inducing a neu
rostimulation signal directed to the regions of the Subjects
brain that possess irregular activity for a time sufficient to
normalize the EEG signals of the regions of the subjects
brain that possess irregular activity.
It is preferred that the time be between one second and one
hour. It is more preferred that the time be between 1 and 30
minutes. It is even more preferred that the time is between 1
minute and 10 minutes. It is even more preferred still that the
time be between 1 minute and 3 minutes. It is still more
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preferred that the time be between 1 second and 30 seconds.
It is most preferred that the time be between 1 second and five
seconds
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Additionally, further EEG signal measurements from the
regions of the Subject's brain that possess irregular activity
are monitored during the administration of the therapy and the
neurostimulation signal is adjusted based on any detected
changes in the additional EEG signal measurements. The
normalization of the EEG signals from the regions of the
Subject's brain that possess irregular activity results in an
alleviation of the symptoms of the neurological disorders.
The neurostimulation signal comprises a carrier frequency
which comprises the dominant frequency and the frequency
offset. It is preferred that the frequency offset be between -10
and 20 hertz.

55

disentrainment.

Some neurological dysfunctions that may be treated by the
present invention include traumatic brain injury, post trau
matic stress disorder, post stroke paralysis, post traumatic
brain injury paralysis, cerebral palsy, headache, depression,
post chemotherapy cognitive, mood and fatigue disorder,
fibromyalgia, memory loss, coma, attention deficit disorder,

10
the neurological dysfunction in order to obtain EEG results
and evaluating the obtained EEG results to determine whether
any region of the Subject’s brain possesses irregular activity
as compared to other regions of the Subjects brain. It is
preferred that the subject be a mammal and, more preferably,
a primate. It is most preferred that the subject be a human
being. It is also preferred that the irregular activity be deter
mined by comparing the EEG signals from a region of the
subject’s brain with the EEG signals from the remaining
regions of the subjects brain. It is also preferred that the EEG
signals are obtained from more than one region of the Sub
ject's scalp. It is even more preferred that the EEG signals be
obtained from at least 21 regions of the subject’s scalp that
correspond to 21 regions of the subjects brain. It is preferred
that the regions be selected according to the International
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It is preferred that the normalization of the regions of the
Subject's brain that possess irregular activity result in these
regions transmitting EEG signals which are close to the pre
determined frequency and amplitude expected for those
regions of the subjects brain. It is even more preferred that
these regions transmit EEG signals at the predetermined fre
quency and amplitude expected for those regions of the Sub
ject's brain after the treatment.
The Subject may require multiple exposures to the method
in order to achieve an alleviation of the symptoms he or she
suffers from the neurological dysfunctions. It is preferred that
the multiple exposures remain in the range of 1 to 40 expo
Sures. However, more exposures are permitted, if required. It

US 8,280,502 B2
11
is more preferred that the exposures remain in the range of 10
to 30 exposures. It is more preferred that the exposures remain
in the range of 5 to 10 exposures. Additionally, it is preferred
that a repeated use of the method be avoided within 24 hours
of a previous use of the method. However, if required, it is
possible to treat more than one region of the subject’s brain (if
more than one region of the Subjects brain possesses irregu
lar activity) in one treatment session.
Additionally, the Subject may be medicated, sedated, or
unconscious during the administration of the method. How
ever, it is preferred that the subject be in none of these con
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ditions.

Regarding the application of the neurostimulation signal
itself, after the identification of regions the subjects brain
which possess irregular activity, neurostimulation treatment
is accomplished by placing EEG sensors in an arrangement
that allows for the measurement of the EEG activity from the
dysfunctional region, as well for providing a successful deliv
ery of current from the EEG sensors into a system ground.
The computer-controlled system in the preferred embodi
ment of the present invention acquires EEG signal data from
the sensor sites and conducts an analysis of the EEG signal
data to determine the frequency of the low frequency carrier
signal component of the AMPWM signal.
The AMPWM signal can be transmitted to the subject
through a plurality of neurostimulation delivery modes. In a
preferred embodiment of the present invention the preferred
mechanism of delivery is accomplished by inducing the
AMPWM signal into the EEG sensors through inductive cou
pling. Another preferred mechanism is to use the AMPWM
signal to drive a light-generating component. Such as a light
emitting diode, to provide a photic stimulation signal that
may be delivered to the patient through the optic nerve.
Another preferred embodiment involves the simultaneous
use of stimulation delivery by inducing the AMPWM signal
into the EEG sensors through inductive coupling and drive a
light-generating component, such as a light emitting diode, to
provide a photic stimulation signal. In essence, this is a com
bination of previously discussed embodiments.
Lastly, it is preferred that EEG leads be placed on the scalp
regardless of what stimulation method is used because the
apparatus and method preferably measures EEG during
stimulation delivery, and uses these EEG measurements to
drive neurostimulation signal parameters.
In a preferred embodiment of the present invention, deliv
ery mode is selectable to account for different levels of sen
sitivity and tolerance in patients. It is also possible to com
pletely automate the process of transmitting the
neurostimulation signal and the monitoring of the EEG signal
data from the EEG sensors.

As stated above, it is preferred that the EEG signals from
the subject be measured at typically 21 different scalp loca
tions and it is preferred that power spectral density computa
tions are performed on the obtained EEG signals. These com
putations break the measured analog EEG signals into
frequency domain data such as a Fourier series of discrete
frequency components, which is limited to 1-42 Hertz
(greater signal components exist and could be utilized, but the
1-42 Hertz range is typically considered clinically useful).
However, other methods of obtaining the frequency domain
data are acceptable (such as the use of wavelet analysis).
In analyzing EEG signal data, frequency bands are com
monly used. For example, the “delta” band is typically 1-4
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CARRIER FREQUENCY=DOMINANT FRE
QUENCY+FREQUENCY OFFSET
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The parameters the clinician uses are (1) stimulation inten
sity, (2) the times that the stimulation signal is turned on in the
treatment cycle (as well as the number of times), (3) the
duration that each stimulation signal is turned on, the leading
frequency of each stimulation event, and (4) the phase offset
of each stimulation event. Intensity is defined by the pulse
width-modulation duty cycle, and ranges from 0 (no "on
time') to 100% (no “off-time'). Thus, an intensity of 50%
would have a duty cycle such that “on-time' is equal to
“off-time' in each pulse cycle. The number of stimulation
cycles and the times that the stimulation turns on is entirely
clinician driven. However, it is preferred ranges that the
stimulation cycles range between 1 Stimulation event up to
50. It is preferred, however, that no more than 20 different
stimulation events be used per session. The preferred leading
frequency is already defined to range between -10 and 20 Hz.
Preferred Phase offset ranges from -180 to 180 Hz.
In this formula, “frequency offset is preferably selected
from the range of -40 to 40 Hertz and more preferably from
-10 and 20 Hertz.
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The offset is chosen by clinical experience, therefore, one
of ordinary skill in the art would recognize how to choose an
offset. However, the clinician generally picks the largest off
set (i.e., +20 Hz) to see ifa response is elicited. If no response
is elicited, lower offsets will be tried until a response is
obtained. The clinician’s choice of parameter values is typi
cally driven by a selection of choices that cause the subject to
react, but yet do not cause an “over-reaction' which is an
adverse effect characterized by short-term fatigue, headache,
etc
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Hertz, the “theta' band is 5-7 Hertz, and so on. For each site,

the total amplitude associated with each discrete frequency
component is assigned to proper bands, providing a measure
of the EEG band energy for each of the aforementioned sites.
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From this, a graphic “image' is generated where colors rep
resent amplitudes. From this image, the clinician can see EEG
band activity related to regions of the brain, and based on
clinical knowledge, can determine if a region has unusual or
abnormal activity.
Accordingly, the neurostimulation phase of the process
(i.e. treatment) is administered to correct regions of abnormal
activity. The administration of the neurostimulation signal is
preferably performed after the imaging process described
above is completed. The clinician preferably applies EEG
sensors to regions of the Scalp that relate to the regions of
suspected dysfunction and the EEG signal data is preferably
re-measured for a period long enough to provide power spec
tral density data (as in the imaging process). The frequency
domain data is then Sorted, and the frequency that exhibits the
highest amplitude is designated the "dominant frequency’.
According to clinician chosen stimulation time and frequency
parameters, a neurostimulation signal is generated that has a
“carrier frequency” that is determined by the formula:
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All of the preferred neurostimulation parameters to be
considered are defined below. Values of these parameters are
chosen based on clinician experience, and are selected in a
manner that is meant to cause a reactive therapeutic effect
without causing the subject to over-react. The selection of
these values is further driven by subject condition and symp
tomatic presentation. For example, a Subject with mild trau
matic brain injury may be able tolerate a longer (in duration)
than average stimulation application without Suffering an
adverse effect. However, a subject with Fibromyalgia with
severe fatigue may only tolerate a very short (in duration)
stimulation burst at the lowest intensities possible. The ranges
of values for these parameters are provided for the clinician to
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choose based on experience, patient condition and symptom
atic presentation, thus no preferred or optimal values exist.
These parameters include:
Intensity. This is a measure of the pulse width modulation
signals duty cycle. This provides a variation on the time
averaged current delivered to the stimulation mechanisms
(i.e. the EEG lead inducing circuit and the photic stimulators).

ZEQUIVALENT = 1 + 2fRC

Duration. This is a measure the time in seconds that a

neurostimulation event (i.e. a period of stimulation signal
output) lasts. This can range from 1 second to 1,200 seconds
in the preferred embodiment.
Start Time This is the time in seconds after the beginning
of a neurostimulation treatment session begins when a neu
rostimulation event starts to occur. There is no specific limi
tation on this, that is, the start time could begin at any time
after the treatment session begins. Before the start time
occurs, the system is simply measuring EEG and this could,
theoretically, go on indefinitely.
Leading Frequency and Phase Offset are previously
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tion.

The effects of applying electrical energy to brain tissues,
the electrical energy is known in this disclosure as a neuro
stimulation signal, are well established in the medical litera
ture and in other teachings, and will not be expounded upon
here.

defined.

By adding the frequency offset to the dominant frequency,
a carrier frequency is created that is always different than the
dominant frequency. This neurostimulation signal is then
either induced in the EEG sensors attached to the subjects
Scalp or the neurostimulation signal is used to drive light
emitting diodes for photic stimulation purposes. The duration
of the signal, along with other parameters (as described
above) such as intensity and phase offset (in the case of LEDs
for photic stimulation—a phase offset causes the LEDs to
flash out of synchronization with each other) are determined
by the clinician's chosen treatment protocol.
As described above, the neurostimulation signal can be an
amplitude modulated pulse-width modulation signal. A
graphic representation of the signal is shown in FIG. 2. In
other words, the carrier frequency simply turns an electric
signal on and off in a way that a square-wave pulse train is
generated with a frequency equal to the carrier frequency.
Thus, in a period (period=1/frequency) of this pulse train,
there will be an amount of time that the electric signal is “on”
and an amount of time when the signal is “off” (see FIG. 2).
During the time that the carrier signal is “on”, the electricity
is further pulsed at a very high frequency. A pulse width
modulator is used to control this high frequency pulsing. By
varying the pulse width, the average current applied is varied.
This is what varying the “intensity” means. With a very low
duty cycle, there is very little average current and thus the
neurostimulation signal has very low intensity. Conversely, a
higher duty cycle delivers more current and thus the intensity
increases. A 100% duty cycle means that there is no “high
frequency off time', and thus the entire neurostimulation
signal is a simple square wave pulse train with frequency
equal to the carrier frequency.
Regarding the apparatus, FIG. 3 presents a model of the
apparatus of the present invention. In FIG. 3., tissue imped
ance 6 is represented by a parallel combination of a simple
resistor 1 and a simple capacitor 2. A Voltage source 3 pro
vides electricity at a supply electrode 4 interfaced at a sub
jects skin 7, with the electricity passing through the tissue
impedance 6 and ultimately being returned to a common
ground 5 potential. Following fundamental circuit analysis,

the equivalent impedance (Zor-Evr) of the circuit is
given by the formula:

In this formula, the resistance is given by the nomenclature
R, capacitance by Cand frequency by f. This equation clearly
shows that as the frequency of the signal increases, the overall
impedance of the system decreases despite the level of imped
ance from the resistor 1 being constant. Although the imped
ances of the composite tissues of the head are considerably
more complex and require a far more Sophisticated model to
accurately describe current flows, this model provides a
simple analogy and approximately describes the effect, and is
a fundamental basis for the disclosure of the present inven

25

30

As stated above, the invention is also directed to an appa
ratus for neurostimulating a subject. The apparatus comprises
a computing device that is operatively coupled to a neuro
stimulator, and a series of EEG sensors that are coupled to the
neurostimulator. Examples of appropriate computing devices
are microprocessors or computers. However, any processing
unit can be used in the present invention as a computing
device. These components are coupled to each other via elec
trical conduction paths. For example, the neurostimulator
could be coupled to the computing device with RS232 cable,
USB cable, etc. Further, the EEG sensors can be coupled to
the neurostimulator with an electrical connector. However, in
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both instances, other methods of coupling the components are
acceptable. The EEG sensors are configured (1) to be attached
to the subject, (2) to monitor EEG signals of a subject, and (3)
to administer neurostimulation signals to the Subject. Addi
tionally, the EEG sensors comprise at least one positive con
tact, at least one negative contact, and at least one ground

40 COntact.
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The apparatus further comprises a biopotential acquisition
device, at least one filtering unit, an isolation amplifier, and a
microcontroller. A preferred microcontroller is the Toshiba
TMP95EY64. However, any comparable microcontroller
may be used. The biopotential device is operatively coupled
to the computing device, and the neurostimulator is config
ured to transmit the biopotential data and EEG signal data to
the biopotential acquisition device. These components may
be coupled together in the manner set forth previously or in
any additional manner that permits their correct usage. Addi
tionally, the biopotential acquisition device is configured to
transmit the EEG data and biopotential data through at least
one circuit or numerical filter and through an isolation ampli
fier which is operatively coupled to the microcontroller. Fur
thermore, it is preferred that the isolation amplifier be capable
of performing “notch' filtering (i.e., eliminate 60 Hz line
noise) and it can be selected from any component found on
the market. It is preferred that it be a Burr-Brown ISO-100.
It is preferred that the filtering unit be selected from the
group consisting of a circuit configured to filter data and a
numerical filter. It is also preferred that the biopotential acqui
sition device is a biopotential amplifier or a high resolution
analog-to-digital converter.
The neurostimulator comprises a biopotential acquisition
unit comprising an electric circuit configured to acquire bio
potential data from the EEG signals obtained by the EEG
sensors attached to the Subject. The biopotential acquisition
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unit is also configured to analyze and store the acquired
biopotential and EEG data with computational means and it is
operatively coupled to the neurostimulator. The neurostimu
lator also comprises a transmission unit configured to trans
mit the biopotential and EEG data from the neurostimulator
to the computing device and an I/O (input/output) unit con
figured to adjust for a time lag in the biopotential and EEG
data being transmitted. The neurostimulator also comprises at
least one Switching unit configured to manage a neurostimu
lation signal.
It is preferred that the subject is a mammal. It is further
preferred that the subject be a primate and even more pre
ferred that the subject is a human being. It is also preferred
that the Switching device is a transistor.
Additionally, the neurostimulator comprises an inductor,
acting as a transformer, whereas the stimulation signal is
induced in the neurostimulator by inducing electrical current

16
signal and deliver the neurostimulation signal to the patient. It
is preferred that a Teledyne A110-2 amplifier be used.
In a preferred embodiment of the present invention, EEG
signals are acquired with EEG sensors 11 attached to a
patient’s scalp. At the end of the EEG sensors 11 attached to
the patient are contact electrodes 25. The EEG signal is deliv
ered to the neurostimulator 9 via the EEG sensors 11, con
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into the inductor, which further induces electrical current in

the EEG sensors via electromagnetic coupling, and thereby
into the subject.
The neurostimulator can further comprise an optical unit
which further comprises a set of light generating devices
located in close proximity to the pupils of the subject. It is
preferred that the light generating devices are light-emitting
diodes.

25

With reference to the accompanying FIG. 1, a preferred
embodiment of the present invention is described where a
computing device 8 is operatively coupled to a peripheral
device henceforth referred to as a neurostimulator 9, such as

through a peripheral cable 10. However, a peripheral cable is
not the only method of coupling the neurostimulator to the
computing device. The neurostimulator 9 further comprises a
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series of electrical conductors henceforth referred to as EEG

sensors 11. The EEG sensors 11 consist of at least one positive
lead 12, one negative lead 13 and one ground lead 14. How
ever, the at least one positive lead 12, one negative lead 13.
and one ground lead 14 may also be incorporated into one
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SensOraS COntactS.

In a preferred embodiment of the present invention,
employing multiple sets of EEG sensors 11 simultaneously
and multiple biopotential acquisition devices 15 can accom
plish acquisition of EEG signals from multiple sites on the
scalp. For clarity, the preferred embodiment is described with
for acquisition of EEG signal from one scalp site. All EEG
sensors 11 are connected to the neurostimulator 9 via EEG
sensor connectors 17.

The neurostimulator 9 can further comprise, as a possible
means of delivering the stimulation signal, an optical unit 16
that is electrically coupled to the neurostimulator 9 via optical
device sensors connectors 19. The optical unit 16 can be
connected to the neurostimulator 9 by an optical device cable
18. However, other means of connecting the optical unit to the
neurostimulator are acceptable. The optical device further
comprises light generating devices 20 located to be in close
proximity to the subject’s eyes. In the preferred embodiment,
the light generating devices 20 are light emitting diodes 21.
The neurostimulator 9 is operated by any number of pos
sible power Supply 22 Sources. To assure electrical isolation
for the patient’s safety, an isolated power supply 23 is utilized
in the preferred embodiment. Further, the neurostimulator 9 is
housed in a protective outer enclosure 24.
The neurostimulator 9 preferably internally comprises the
biopotential acquisition device and the biopotential acquisi
tion device is preferably designed to acquire biopotential data
from EEG signal data, specifically patient EEG, to provide a
means for analysis and data storage of the biopotential data
through computational means, generate a neurostimulation
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nected to the biopotential acquisition device 15 through EEG
lead connectors 17 and operatively coupled to a biopotential
acquisition device 15 Such as a biopotential amplifier or high
resolution analog-to-digital converter. To minimize the effect
of external electrical noise, any number of circuit or numeri
cal filters 26 may be employed in the preferred embodiment.
To assure patient safety, the biopotentials are passed through
an isolation amplifier 27. The output of the biopotentials, after
passing through the biopotential acquisition device 15, filters
26 and isolation amplifier 27 is acquired by a microcontroller
28 through analog-to-digital ports 29. The microcontroller 28
is operatively coupled to the computing device 8. One method
of coupling the microcontroller to the computing device is to
use a peripheral cable 10. Control of the neurostimulator 9 is
accomplished by communication between the microcontrol
ler 28 and the computing device 8. Further, the objective of
biopotential data analysis and storage is accomplished com
putationally via communication between the microcontroller
28 and the computing device 8.
After analysis of the acquired biopotential, that is, the EEG
signal, the computing device 8 communicates proper stimu
lation signal parameters, in accordance with the present
invention, to the microcontroller 28. These parameters
include signal energy level, frequency of the low frequency
component of an AMPWM signal, phase offset of multiple
signals, start time, frequency offset and duration through a
user interface. Utilizing a digital-to-analog port 30 on the
microcontroller 28, the stimulation signal is output from the
microcontroller 28 to transistors 31 or similar switching
devices capable of managing the current levels of the stimu
lation signal. Depending on the mode of Stimulation chosen
by a clinician, the stimulation signal will be routed to the
different means of stimulation signal delivery, alone or in
combination. The parameters for the clinician’s choice are set
forth above.
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If optical stimulation is desired, the stimulation signal will
be sent to the optical unit 16 featuring the light generating
devices 20 to be worn by the patient. Any unit capable of
emitting light may be used as a light generating device. This
includes, but is not limited to a LED, a lightbulb, a low-power
laser, etc. Alternately, if EEG lead 11 stimulation is desired,
where the stimulation signal is delivered to the patient's scalp
via the attached electrodes 25, then the stimulation signal is
sent to an inductor 32 which is designed to induce current in
the EEG sensors 11 from the stimulation signal generated by
the microcontroller 28. In the preferred embodiment of the
present invention, a plurality of stimulation delivery modes is
warranted to allow for clinician choice to further effect suc

cessful treatment based on individual patient needs.
To assure patient safety, all electronics in the neurostimu
lator 9, including the biopotential acquisition device 15, the
filter 26, the isolation amplifier 27, the microcontroller 28 and
the transistors 31 are supplied electricity by the aforemen
tioned isolation power supply 23.
Finally, regarding the coupling of the components, if a
computing device is used it is preferably operatively coupled
to the processor of the neurostimulator via any of a number of
means of commonly used peripheral communications tech
niques, such as serial communication, USB port communi
cation or parallel communication 10. All remaining electron
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ics are preferably operatively coupled to the processing
device (e.g. microcontroller) in the neurostimulator. The data
acquisition circuit preferably comprises the biopotential
acquisition device 15, filters 26 and isolation circuitry (ampli
fier) 27. The isolation amplifier is preferably coupled to an
analog-to-digital input port on the microcontroller 28, via
electrical conduction paths. Such as wires or printed circuit
board conductors. The filters 26 are preferably operatively
coupled to the isolation amplifier 27 via electrical conduction
paths such as wires or printed circuit board conductors. Fur
ther, the biopotential acquisition device 15 is preferably
operatively coupled to the filters 26 via electrical conduction
paths such as wires or printed circuit board conductors.
EEG leads 11 are preferably coupled to the biopotential
acquisition device 15 via electrical connectors 17, providing
conduction of EEG electricity at the scalp to the biopotential
amplifier 15.
A stimulation circuit is preferably coupled to a digital-to
analog port 30 on the microcontroller, in all cases via electri
cal conduction paths. Such as wires or printed circuit board
conductors. It is preferred that an isolated power supply 23
Supplies all operative power for neurostimulation outputs
such as that to the optical device 16 or the EEG lead stimu
lation inducing circuitry 32. Electrical output from the digi
tal-to-analog port30 is preferably conducted to a transistor 31
that is further coupled to the isolated power supply 23. When
a signal is received at the base of the transistor 31 from the
microcontroller 28, the transistor operates to switch on elec
tricity from the isolated power supply 23 which is further
conducted via electrical coupling to the inductor (stimulation
inducing circuitry) 32. Current flow in the inductor 32
induces a current in the EEG lead, as described in the speci
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5. "Centromedian-thalamic and hippocampal electrical
stimulation for the control of intractable epileptic sei
Zures’, Velasco M, Velasco F, Velasco A. L. J. Clin Neuro

physiol 2001 November; 18(6):495-513
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We claim:
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Alternately, for photic stimulation, the isolated power Sup
ply 23 is preferably coupled via electrical coupling to two
more transistors 31, which are preferably operatively coupled
via electrical coupling to independent digital-to-analog ports
30 on the microcontroller 28. Electricity conducted from the
digital-to-analog ports 30 to the base of the transistors 31 in
the photic stimulation circuit has the effect of switching on
these transistors, further allowing for conduction of electric
ity to the photic stimulation devices, such as LEDs 21. The
photic stimulation devices are preferably coupled to the tran
sistors 31 via electrical connectors 19, thus providing for
current flow to the photic stimulation devices such as LEDs
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Finally, it is preferred that the apparatus operate on a 12
Volt power Supply. It is more preferred that the apparatus
operate on a 6 volt power supply. It is most preferred that the
apparatus operate on a power Supply equivalent to the lowest
power Supply requirement of the components used.
The following references are incorporated by reference in
their entirety:
1. “High-frequency stimulation of the subthalamic nucleus
silences Subthalamic neurons: a possible cellular mecha
nism in Parkinson's Disease', Magarinos-Ascone C, Pazo
J H Macadar O and Buno W. (Neuroscience 2002: 115(4):
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trical stimulation and treatment; and

1109-17.

2. “The spatial receptive field of thalamic inputs to single
cortical simple cells revealed by the interaction of visual
and electrical stimulation', Kara, Pezaris J. S. Yurgenson S

a transmission device coupled to the signal generator,
60
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1. A system for providing external electrical stimulation
and treatment for a disorder by electrically stimulating and
treating neurological tissue of a region of a brain, the system
comprising:
means for generating an amplitude-modulated pulse-width
modulation (AMPWM) signal, the AMPWM signal
including a high frequency signal component and a low
frequency signal component, wherein the high fre
quency signal component is amplitude-modulated and
pulse-width modulated, wherein the high frequency sig
nal component has a sufficiently high frequency to
enable the AMPWM signal to penetrate high impedance
portions of tissue located between external EEG sensors
placed on a scalp and the neurological tissue of the
region of the brain being stimulated, wherein the low
frequency signal component is of Sufficiently low fre
quency to provide the electrical stimulation and treat
ment, and wherein the low frequency signal component
dynamically varies in frequency over time; and
means for transmitting the AMPWM signal from a neuro
stimulation device to the neurological tissue of the
region of the brain being stimulated via the external EEG
sensors placed on the scalp.
2. The system of claim 1, wherein the neurostimulation
device and EEG sensors are externally located relative to the
tissue and the neurological tissue of the region of the brain.
3. The system of claim 1, wherein the disorder to be treated
is a neurological disorder.
4. The system of claim 1, further comprising means for
simultaneously providing electrical stimulation and measur
ing of an overlapping Voltage.
5. The system of claim 4, wherein the overlapping voltage
is an electroencephalogram (EEG) signal.
6. A system for providing external electrical stimulation
and treatment for a disorder by electrically stimulating and
treating neurological tissue of a region of a brain, the system
comprising:
a signal generator for generating an amplitude-modulated
pulse-width modulation (AMPWM) signal, the gener
ated AMPWM signal including a high frequency signal
component and a low frequency signal component,
wherein the high frequency signal component is ampli
tude-modulated and pulse-width modulated, wherein
the high frequency signal component has a Sufficiently
high frequency to enable the generated AMPWM signal
to penetrate high impedance portions of tissue located
between external EEG sensors placed on a scalp and the
neurological tissue of the region of the brain being
stimulated, wherein the low frequency signal compo
nent is of sufficiently low frequency to provide the elec
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wherein the transmission device transmits an electrical

stimulation and treatment signal from the generated
AMPWM signal, and wherein the transmitted electrical
stimulation and treatment signal is communicated from
the neurostimulation device to the neurological tissue of
the region of the brain being stimulated via the external
EEG sensors placed on the scalp to electrically stimulate
and treat the disorder.
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7. The system of claim 6, wherein the neurostimulation
device and EEG sensors are externally located relative to the
tissue and the neurological tissue of the region of the brain to

20
16. The system of claim 15, wherein the sensor coupled to
the processor and the lead for the transmission is the electro
encephalogram (EEG) sensor.
17. The system of claim 15, wherein the system is capable
of simultaneous electrical stimulation and receipt of informa

be treated.

8. The system of claim 6, wherein the low frequency signal
component dynamically varies in frequency over time.
9. The system of claim 6, wherein the disorder to be treated
is a neurological disorder.
10. The system of claim 6, wherein the electrical stimula
tion and treatment signal includes an external stimulation
signal that drives an external stimulation device.
11. The system of claim 10, wherein the external stimula

tion from the at least one reference site of the tissue located

10

tion device is an audio stimulation device.

12. The system of claim 10, wherein the external stimula
tion device is an optic stimulation device.
13. The system of claim 10, further comprising:
a processor coupled to the signal generator, the processor
being capable of controlling the signal generator.
14. The system of claim 13, further comprising:
a sensor coupled to the processor, the sensor being capable
of receiving information from at least one reference site

hertz -43 hertz.
15

nal.

15. The system of claim 14, wherein the sensor coupled to
the processor is a lead for the neurostimulation device that
transmits the electrical stimulation.

20. The system of claim 19, wherein the high frequency
signal component is in the range of 1,000 hertz -100,000
hertz.

21. The system of claim 19, wherein the high frequency
signal component is in the range of 10,000 hertz -20,000
hertz.

of the tissue located between the neurostimulation

device and the neurological tissue of the region of the
brain being stimulated, wherein information from the
sensor is a parameter in determining the AMPWM sig

between the neurostimulation device and the neurological
tissue of the region of the brain.
18. The system of claim 14, wherein the sensor is capable
of receiving electroencephalogram (EEG) information.
19. The system of claim 1, wherein the high frequency
signal component is in the range of 43 hertz to 1,000,000 hertz
and the low frequency signal component is in the range of 1
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22. The system of claim 6, wherein the high frequency
signal component is amplitude-modulated and pulse-width
modulated so as to control a time-averaged current of the
AMPWM signal when passing through a conducting
medium, wherein the conducting medium comprises the tis
Sue located between the external EEG sensors placed on the
Scalp and the neurological tissue of the region of the brain
being stimulated.

